Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BLU-782 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single ascending doses with BLU-782 | EXPERIMENTAL | - |
| Single ascending doses with placebo | PLACEBO_COMPARATOR | - |
| Multiple ascending doses with BLU-782 | EXPERIMENTAL | - |
| Multiple ascending doses with placebo | PLACEBO_COMPARATOR | - |
| Food effect of BLU-782 taken with food | EXPERIMENTAL | - |
| Food effect of BLU-782 taken without food | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BLU-782 | DRUG | oral capsules |
| Placebo | DRUG | oral capsules |
| BLU-782 taken with food | DRUG | oral capsules |
Inclusion Criteria: * Medically healthy * Non-smoker * Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2 * No clinically significant cardiac history * No current electrocardiogram (ECG) abnormality * Female must not be of childbearing potential Exclusion Criteria: * History of or current mental or legal ...
BLU-782 is an investigational small molecule developed by Blueprint Medicines Corporation. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been publicly disclosed, and it remains in early clinical development.
BLU-782 is being developed by Blueprint Medicines Corporation, which trades on the Nasdaq under the ticker symbol BPMC. The company sponsored the Phase 1 study of BLU-782 conducted in the United States.
BLU-782 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
BLU-782 has been evaluated in one completed Phase 1 trial, NCT03858075, titled Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults. The trial enrolled 108 healthy volunteers in the United States and was randomized, double-blind, and placebo-controlled.
The Phase 1 trial NCT03858075 evaluated the safety, tolerability, pharmacokinetics, and food effect of BLU-782 in healthy adults. It enrolled 108 participants aged 19 years and older of all sexes in the United States. The study was randomized, double-blind, and placebo-controlled, and it has been completed.